Integra LifeSciences (NASDAQ:IART) Share Price Passes Above 200 Day Moving Average - Here's What Happened

Key Points

• Integra LifeSciences shares crossed above their 200-day moving average, reaching $16.94 before closing at $16.74, compared with a 200-day average of $14.05.
• Analyst sentiment remains cautious: the stock has a consensus “Reduce” rating, with one Buy, five Holds and two Sells, and an average price target of $18.86.
• Integra exceeded quarterly expectations, reporting $0.56 in EPS versus the $0.48 consensus and revenue of $418.76 million; institutional investors own approximately 84.78% of the shares.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $14.05 and traded as high as $16.94. Integra LifeSciences shares last traded at $16.74, with a volume of 551,041 shares.

Analysts Set New Price Targets

Several analysts recently weighed in on IART shares. UBS Group assumed coverage on Integra LifeSciences in a report on Tuesday, July 28th. They issued a "neutral" rating and a $19.00 target price on the stock. Wells Fargo & Company upped their price target on Integra LifeSciences from $15.00 to $18.00 and gave the stock an "equal weight" rating in a report on Thursday, July 30th. Weiss Ratings upgraded Integra LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 14th. Truist Financial increased their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the company a "hold" rating in a research report on Thursday, July 16th. Finally, Wall Street Zen downgraded shares of Integra LifeSciences from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus target price of $18.86.

Integra LifeSciences Trading Up 0.9%

The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -185.98, a P/E/G ratio of 1.40 and a beta of 1.21. The business has a 50-day moving average of $17.99 and a two-hundred day moving average of $14.05.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The firm had revenue of $418.76 million during the quarter, compared to analysts' expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hsbc Holdings PLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at $879,000. Tejara Capital Ltd lifted its holdings in shares of Integra LifeSciences by 42.6% during the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company's stock worth $2,134,000 after acquiring an additional 51,300 shares during the period. UBS Group AG boosted its position in shares of Integra LifeSciences by 211.7% during the 4th quarter. UBS Group AG now owns 408,969 shares of the life sciences company's stock valued at $5,079,000 after acquiring an additional 277,745 shares in the last quarter. Glenmede Trust Co. NA boosted its position in shares of Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company's stock valued at $9,276,000 after acquiring an additional 211,774 shares in the last quarter. Finally, Systematic Financial Management LP increased its stake in Integra LifeSciences by 4.5% in the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company's stock valued at $13,769,000 after acquiring an additional 48,094 shares during the period. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source